China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

LongBio Pharma, a prominent developer of innovative treatments for allergic and autoimmune diseases in China, successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange on June 5, 2026. The company issued shares at a price of HK$96.06, which opened at HK$144.30, leading to a market capitalization of approximately HK$10.7 billion. This IPO marks a significant achievement for LongBio Pharma and its major institutional investor, Qiming Venture Partners, which has backed the company through multiple financing rounds.

Founded in 2020, LongBio Pharma specializes in the discovery and development of biopharmaceuticals targeting various allergic and autoimmune conditions. The company's founding team boasts extensive experience in drug development, with Dr. Sun Naichao, a co-founder, recognized as the original inventor of omalizumab, the first anti-IgE antibody. The firm has developed a robust product pipeline, including its core product LP-003, a novel anti-IgE antibody that has shown superior efficacy compared to omalizumab in treating chronic spontaneous urticaria (CSU). Another key product, LP-005, is a bi-functional complement antibody-fusion protein that targets both C5 and C3b, positioning LongBio Pharma at the forefront of global therapeutic innovation.

Qiming Venture Partners has played a crucial role in LongBio Pharma's growth, having invested as the lead investor in its B2 financing round in 2024 and as a co-lead in the C round in 2025. Prior to the IPO, Qiming held a 4.27 percent stake in the company, underscoring its commitment to supporting LongBio Pharma's transition from laboratory research to commercial viability. The successful IPO is viewed as a pivotal milestone for the company, enhancing its capacity to address the rising prevalence of allergic diseases in China, including allergic rhinitis, asthma, and chronic urticaria.

The healthcare sector in China is experiencing significant growth, driven by increasing demand for innovative treatments and a rising incidence of allergic conditions. LongBio Pharma's listing reflects broader trends in the biotechnology space, where companies focused on addressing unmet clinical needs are attracting substantial investor interest. The successful market debut of LongBio Pharma is expected to encourage further investments in the sector, particularly in firms that demonstrate strong research capabilities and a commitment to innovation.

In conclusion, LongBio Pharma's IPO not only highlights the company's achievements but also signals a positive outlook for the healthcare investment landscape in China. As the market continues to evolve, Qiming Venture Partners is likely to pursue additional opportunities in the biotechnology sector, reinforcing its strategy of investing in cutting-edge medical innovations that address pressing health challenges. The successful listing of LongBio Pharma may serve as a catalyst for other companies in the sector, potentially leading to a wave of new public offerings that further enhance the visibility and viability of the Chinese biotechnology market.